Population pharmacokinetics of mefloquine given as a 3-day artesunate–mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai–Myanmar border

Table 2 Parameter estimates from the pharmacokinetic model describing mefloquine

	Parameter value (%RSE)^ab	95% CI^b	IIV %CV (%RSE)^ab	95% CI^b	Shrinkage (%)^a
CL/F (l/h)	2.77 (4.81)	2.52–3.04	38.0 (14.8)	27.1–48.0	33.7
Vc/F (l)	359 (3.38)	335–384	–	–	–
MTT (h)	3.89 (5.18)	3.54–4.32	43.6 (11.5)	33.7–53.0	18.5
Q/F (l/h)	11.7 (8.37)	10.1–13.9	55 (27.3)	22.4–80.5	50.8
Vp/F (l)	474 (8.02)	406–554	63.1 (15.5)	43.9–81.7	43.2
σ²	0.0902 (18.7)	0.0591–0.124	–	–	17.9

σ² is the variance of the residual error. %RSE is the relative standard error calculated as 100 × median/(standard error). CV% is calculated as 100 × SQRT (EXP(ω²) − 1). The 2.5th and 97.5th percentiles are used to present the 95% CI (95% confidence interval)
CL/F, apparent elimination clearance; Vc/F, apparent volume of distribution of the central compartment; MTT, mean transit time of the absorption; Q/F, apparent inter-compartmental clearance; Vp/F, apparent volume of distribution of the peripheral compartment; F, relative bioavailability
^aFrom NONMEM
^bFrom bootstrap run with 958 successful runs (out of 1000)

ISSN: 1475-2875